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Trimethoprim-Sulfamethoxazole Activity and
Pharmacodynamics against Glycopeptide-Intermediate
Staphylococcus aureus
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Cory G. Garvin, Pharm.D., David C. Chen, Pharm.D., and 
Steven J. Martin, Pharm.D.
Study Objective.  To determine the activity of trimethoprim-sulfamethoxazole
(TMP-SMX) against glycopeptide-intermediate Staphylococcus aureus
(GISA).
Design. In vitro study.
Setting. University laboratory.
Measurements and Main Results.  Minimum inhibitory concentrations
(MICs) of TMP-SMX were determined for three GISA strains.  Time-kill
assays were conducted at 1 x MIC and at simulated peak serum
concentrations (Cmax).  Two dosing regimens of TMP-SMX were
investigated:  TMP-SMX 8 mg (TMP)/kg/day and TMP-SMX 15 mg/kg/day,
each divided into two doses/day.  Both dosages were studied against each
strain in a two-compartment in vitro model to determine concentration-
related activity.  All isolates were susceptible to TMP-SMX.  In time-kill
studies at 1 x MIC, TMP-SMX was bacteriostatic against all isolates and
bactericidal against two of three strains at simulated Cmax.  The 15-
mg/kg/day (divided-dose) regimen provided the best overall reduction in
colony-forming units/ml.
Conclusion.  All GISA strains were susceptible to TMP-SMX.  In addition, it
appears that TMP-SMX may have concentration-dependent antibacterial
activity against these organisms.  As an option in the management of GISA
infection, TMP-SMX merits further study.
(Pharmacotherapy 2002;22(8):983–989)
Glycopeptide-intermediate Staphylococcus
aureus (GISA) clinical isolates were first reported
in 1996.1 Since then, several reports of clinical
infection caused by GISA strains have been
published.2–6 Isolates from these infections had
minimum inhibitory concentrations (MICs) for
vancomycin of 8–16 µg/ml.  The mechanism of
resistance of GISA to vancomycin has not been
determined.  All clinical GISA strains also have
been methicillin resistant (MRSA).  Plasmid-
mediated resistance is unlikely to be the
mechanism of resistance, since none of the
isolated strains has contained the vanA or vanB
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gene.7 Resistance may be related to thickened
cell walls or increased penicillin-binding protein
development.8–10 The decreased susceptibility of
these organisms has been associated with
prolonged exposure to vancomycin.  With
removal of vancomycin, some isolates revert to
lower vancomycin MICs.11
Several GISA strains with a common ancestral
clone have vancomycin MICs of 2–8 µg/ml.
Colonies of these strains contain subpopulations
with a vancomycin MIC of 8 µg/ml.  Thus, a
homogeneously resistant population (vancomycin
MIC > 8 µg/ml) is easily obtainable by a one-step
selection with 4–8 µg/ml of vancomycin.12 The
prevalence of heterogeneously resistant strains
may be up to 22% in some hospitals.  This partly
explains the therapeutic failure of vancomycin in
treatment of MRSA infections.12
There is no single drug or drug regimen of
choice for treatment of GISA infections.  Several
antibiotics and combination regimens have been
used clinically, and many more have been
evaluated in vitro.  Newer antibiotics, such as
quinupristin-dalfopristin and linezolid, show
promise as monotherapies, but their effectiveness
against GISA has not yet been confirmed in
clinical studies.13
Trimethoprim-sulfamethoxazole (TMP-SMX)
has excellent in vitro activity against methicillin-
susceptible S. aureus and MRSA.7, 14–20 It is an
accepted alternative to vancomycin for
prevention and treatment of MRSA infections,
and several reports document its efficacy against
these infections.10, 15, 21 In addition, several case
reports describe the susceptibility of clinical
GISA infections to TMP-SMX.2–5, 22 To describe
more fully the activity of TMP-SMX against
GISA, we performed several in vitro tests of
interaction for this drug-organism combination.
These tests consisted of MIC determination,
traditional time-kill analysis, and experiments
with an in vitro pharmacodynamic model.  This
model simulated a compartmental infection
under neutropenic conditions, thus reflecting the
pharmacokinetics of TMP-SMX in critically ill
patients, who represent a population at risk of
infection with MRSA or GISA.23
Materials and Methods
We used three clinical GISA strains in all tests:
992, MU50, and 14379.  In addition, S. aureus
American Type Culture Collection (ATCC) 29213
was used for quality control.  Vancomycin
(Sigma, St. Louis, MO) and TMP-SMX (TMP
Sigma, SMX Sigma) were used for all tests.
Mueller-Hinton broth (Difco, Detroit, MI),
supplemented with calcium chloride 20 µg/ml
and magnesium chloride 10 µg/ml was used for
each experiment.  Mueller-Hinton agar plates
(Remel; Lenexa, KS) were used to maintain the
organisms and for colony counts.  Mueller-
Hinton agar with vancomycin 4 µg/ml was used
for selection of the heterogenous strains MU50
and 14379 before each experiment.
MIC Testing
Microdilution broth MICs for vancomycin and
TMP-SMX were determined according to
guidelines from the National Committee for
Clinical Laboratory Standards (NCCLS).24 The
MICs were evaluated before all experiments and
at 48 hours after model runs for organisms with
residual growth.  An inoculum was prepared
from bacteria in logarithmic growth to match a
0.5 McFarland standard and then diluted to
obtain a final test inoculum of 1.5 x 105 colony-
forming units (cfu)/ml.24 Trimethoprim-SMX
was tested in a physiologic 1:19 ratio.
Concentrations tested were vancomycin
0.0625–128 µg/ml and TMP 0.03125–16
µg/ml–SMX 0.59375–304 µg/ml.  For quality
control, S. aureus ATCC 29213 was included.
Each MIC assessment was performed four times,
and the mode value was selected.
Time-Kill Analysis
Time-kill assays were performed for TMP-SMX
against each GISA strain according to NCCLS
guidelines.25 We tested TMP-SMX at 1 x MIC
and at simulated in vivo peak serum
concentrations (Cmax; TMP 2.45 µg/ml–SMX
46.55 µg/ml).21 An inoculum of 1.5 x 105 cfu/ml
was used for all time-kill assays.  The inoculum
was prepared by placing 1–2 colonies of an
overnight growth of test organisms in Mueller-
Hinton broth, incubating at 35°C on a shaking
platform, and allowing the organisms to come to
logarithmic growth for 3–5 hours.  The inoculum
was diluted in saline to match the density of a 0.5
McFarland standard using a spectrophotometer
(Spectronic 20 Genesys; Milton Roy Co.,
Rochester, NY).  The inoculum was confirmed
with colony counts.  Organism and antibiotic
were added together, and time-kill tubes
containing a total volume of 2 ml were incubated
at 35°C in room air on a shaking platform at 150
rpm.  Samples were removed from each tube at 1,
4, 8, 12, and 24 hours, diluted 1:100 or greater as
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necessary in 0.9% sodium chloride to prevent
antibiotic carryover, and plated on Mueller-
Hinton agar with a spiral dispensing device
(Spiral Biotech, Bethesda, MD).  All plates were
incubated for 24 hours at 35°C in room air.
Bacterial colony counts were determined with a
laser colony counter (Microbiology International,
Rockville, MD) and confirmed by hand counts.
The lower limit of detection for this method is
2.3 log10 cfu/ml.  Reductions in bacteria from
baseline of 3 log10 cfu/ml or greater were
considered to indicate bactericidal activity.  All
time-kill assays were performed in duplicate, and
the mean value (± SD) was determined.
In Vitro Pharmacodynamic Infection Model
An in vitro two-compartment glass infection
model was used to simulate human pharmaco-
kinetics.  In this model, an outer “central”
compartment simulates central blood circulation,
and an inner “peripheral” or “infection”
compartment simulates tissue infection.  Each
organism was tested in the model.  The inoculum
was prepared in a similar fashion to the time-kill
experiments.  Concentrations of TMP-SMX (1:19
physiologic ratio) simulated the pharmacokinetics
of the drug in critically ill trauma patients, a
patient population at risk for GISA infection.
Doses and dosing intervals for TMP-SMX are not
defined clearly.  For this reason, we investigated
two dosing regimens:  TMP-SMX 8 mg
(TMP)/kg/day and TMP-SMX 15 mg/kg/day, each
divided into two doses/day, which yielded Cmaxs
of 3.00 µg/ml and 5.67 µg/ml (shown in TMP
µg/ml), and trough serum concentrations (Cmin)
of 1.26 µg/ml and 2.38 µg/ml, respectively.23
Bacteria were added to the peripheral
compartment, a 10-ml chamber made with a
12,000–14,000 molecular weight cutoff dialysis
membrane (Spectra/Por; Spectrum Labs, Rancho
Dominguez, CA).  This membrane prevents
outward migration of the bacteria yet allows
passage of antibiotics into the compartment.
Antibiotics were injected into the 325-ml central
compartment in a bolus fashion over 15–30
seconds.  Fresh supplemented Mueller-Hinton
broth was introduced to the central compartment
with a peristaltic pump (Masterflex; Cole-Parmer
Instrument Company, Chicago, IL), at a rate to
achieve an antibiotic half-life of 9.6 hours.  The
model was placed in an incubator at 35°C in
room air for the duration of the experiments.
Model experiments were run for 48 hours and
were performed in duplicate.  The mean value (±
SD) was selected.  Growth controls without
antibiotic were performed before the experiments
to ensure adequate bacterial growth in the model.
The MICs were confirmed on each day of
experimentation from the inoculum used in each
experiment, and MICs were repeated on any
residual growth at 48 hours.
Pharmacodynamic Analysis
Aliquots of 50 µl were removed from both
compartments using a sterile syringe and needle
at 0, 2, 4, 8, 12, 18, 24, 30, 36, and 48 hours.
The aliquots were diluted 1:100 or greater as
necessary in 0.9% sodium chloride to prevent
antibiotic carryover and plated logarithmically on
Mueller-Hinton agar with a spiral plating device.
The remaining portions of the samples were
frozen at -70°C for analysis of drug concentration.
All plates were incubated for 24 hours at 35°C in
room air.  Bacterial colony counts were determined
with a laser colony counter and confirmed by
hand counts.  The lower limit of detection for
this method is 2.3 log10 cfu/ml.  All pharmaco-
dynamic assays were performed in duplicate, and
the mean value (± SD) was used.  The difference
in colony count reduction and rate of bacterial
reduction between the two dosages tested was
analyzed using Tukey’s test for multiple
comparison.  A p value of less than or equal to
0.05 was considered significant.
Pharmacokinetic Analysis
Concentrations of TMP-SMX were determined
by removing samples for peak and trough
concentrations from both compartments at each
dosing interval.  Samples were stored at -70°C
until analysis.  Drug concentrations were
determined by bioassay in duplicate with S.
aureus ATCC 29213 as the reference organism.
Results
Minimum Inhibitory Concentration Testing
Each of the three GISA strains tested was
susceptible to TMP-SMX.  The MICs against
TMP-SMX and vancomycin are shown in Table 1.
Time-Kill Analysis
Time-kill curves are shown in Figures 1
(simulated Cmax) and 2 (1 x MIC).  Using
simulated Cmax concentrations, bactericidal
activity for TMP-SMX was observed against
strains 14379 and 992.  Bacteriostatic activity
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occurred against the MU50 strain.  For the 992
strain, TMP-SMX was rapidly bactericidal,
achieving colony counts below the lower limit of
detection at 4 hours.  For GISA 14379, the TMP
concentration was 9.8 times the MIC.  For GISA
Mu50 and 992, the TMP concentration was 39.2
times the MIC.  In the 1 x MIC time-kill assays,
bacteriostatic effects were evident against all
three isolates.
In Vitro Model
The values obtained for peak and trough
pharmacokinetic parameters are shown in Table
2.  Results of the in vitro model experiments are
shown in Figures 3–5.  A 1-log difference was
observed in inoculum at baseline for the 992
control model as compared with the antibiotic-
containing models (Figure 5).  However, growth
characteristics for the 992 control resembled
those of the growth controls of the other isolates
during the first 4 hours.  Both dosing regimens
were bactericidal against the MU50 strain (Figure
986
Table 1.  Minimum Inhibitory Concentration Data
TMP-SMX MIC Vancomycin MIC
GISA Strain (µg/ml) (µg/ml)
14379 0.25–4.75 8
992 0.0625–1.1875 8
Mu50 0.0625–1.1875 8
GISA = glycopeptide-intermediate Staphylococcus aureus; TMP-SMX
= trimethoprim-sulfamethoxazole; MIC = minimum inhibitory
concentration.
Figure 1 .   Time-kill curve for trimethoprim-
sulfamethoxazole at simulated peak serum concentrations
against three glycopeptide-intermediate Staphylococcus
aureus isolates.  CFU = colony-forming units.
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Figure 2.  Time-kill curves for TMP-SMX at 1 x MIC against
three glycopeptide-intermediate Staphylococcus aureus
isolates.  CFU = colony-forming units.
Table 2.  Mean ± SD Peak and Trough Central
Compartment TMP-SMX Concentrations for Model Runs
GISA Dose Peak Trough
Strain (mg) (µg/ml) (µg/ml)
14379 8 3.46 ± 0.23 1.20 ± 0.15
15 5.08 ± 0.10 2.33 ± 0.19
992 8 3.02 ± 0.11 1.12 ± 0.09
15 5.59 ± 0.12 2.33 ± 0.10
MU50 8 3.70 ± 0.03 1.35 ± 0.10
15 5.64 ± 0.11 2.39 ± 0.04
TMP-SMX = trimethoprim-sulfamethoxazole; GISA = glycopeptide-
intermediate Staphylococcus aureus.
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Figure 3 .   In vitro modeling of TMP-SMX 8 mg
(TMP)/kg/day and 15 mg/kg/day, each divided into two
doses/day, against glycopeptide-intermediate Staphylococcus
aureus Mu50.  CFU = colony-forming units.
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3), with organism counts below the limit of
detection within 24 hours.  For strains 14379
(Figure 4) and 992 (Figure 5), the 15-mg/kg/day
regimen provided the best overall reduction in
cfu/ml.  Colony counts fell below the lower limit
of detection by 24 hours with the higher dosing
regimen against 992.  The TMP-SMX MIC for
strain 992 increased to TMP 4 µg/ml–SMX 76
µg/ml at 48 hours (baseline TMP 0.0625
µg/ml–SMX 1.1875 µg/ml) after the 8-mg/kg/day
regimen.  No changes in MIC were observed for
strains 14379 or MU50 at 48 hours.  Bacterial
killing did not begin in any of the models until
4–8 hours, correlating with peak peripheral
compartment drug concentrations.  The
difference in colony count reduction between the
two dosages tested was significant for strain 992
(p=0.03) but not did not reach statistical
significance for strains 14379 or MU50.
Discussion
Clinicians have long used TMP-SMX as an
alternative to synthetic penicillins or vancomycin
in the treatment of S. aureus infection and
colonization.6, 21 Against MRSA, TMP-SMX has
demonstrated good clinical efficacy.  A study
reported an 86% clinical cure rate among 43
patients with MRSA infection treated with TMP-
SMX.21 Another study evaluated the use of TMP-
SMX in six patients with osteomyelitis secondary
to MRSA.15 Five patients experienced complete
responses, and the sixth discontinued therapy
after 2 weeks due to neutropenia.  Several in vitro
studies have found MRSA strains to be
susceptible to TMP-SMX, with the TMP
component of MICs ranging from 0.018-0.5
µg/ml.7, 14–18
In vitro data for TMP-SMX against clinical
GISA strains is also promising, with several
isolates found to be susceptible.2, 3, 7, 19, 22 This
agent was used clinically in one reported case of
GISA infection.  In this case, the GISA isolate
(14379) was susceptible to chloramphenicol,
rifampin, TMP-SMX, and tetracycline.4 The
patient was treated successfully with oral
rifampin 300 mg/day and oral TMP 160 mg/day-
SMX 800 mg/day.  Other clinical reports
document the susceptibility of GISA to TMP-
SMX.  A report from New Jersey described a
GISA isolate (992) susceptible to gentamicin,
TMP-SMX, tetracycline, and imipenem.3, 4 The
patient was treated effectively with vancomycin,
gentamicin, and rifampin, but eventually died.
In the first reported instance of a GISA infection
in France, the GISA strain proved susceptible to
pristinamycin and TMP-SMX after the patient
failed initial treatment with teicoplanin and
amikacin.21 Eradication of the organism occurred
with quinupristin-dalfopristin.  Recently a GISA
infection was reported in Korea.5 A man with a
longstanding MRSA pelvic abscess received long
courses of both vancomycin and teicoplanin.  He
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Figure 4 .   In vitro modeling of TMP-SMX 8 mg
(TMP)/kg/day and 15 mg/kg/day, each divided into two
doses/day, against glycopeptide-intermediate Staphylococcus
aureus 14379.  CFU = colony-forming units.
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Figure 5 .   In vitro modeling of TMP-SMX 8 mg
(TMP)/kg/day and 15 mg/kg/day, each divided into two
doses/day, against glycopeptide-intermediate Staphylococcus
aureus 992.  CFU = colony-forming units.  ap=0.03, colony
count reduction for 8 mg/kg/day versus 15 mg/kg/day.
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died as a result of MRSA sepsis, and his blood
produced a S. aureus isolate with a vancomycin
MIC of 8 µg/ml.  The organism was susceptible to
rifampin and TMP-SMX but resistant to
ciprofloxacin, clindamycin, erythromycin,
gentamicin, and tetracycline.5
Our MIC analyses showed all three GISA
isolates to be susceptible to TMP-SMX.  There are
no data to describe the pharmacodynamic
parameters that best predict organism eradication
in time-kill or other in vitro testing systems with
TMP-SMX.  Most b-lactams and macrolides
exhibit concentration-independent killing,
whereas aminoglycosides and fluoroquinolones
exhibit concentration-dependent killing.
Comparable work has not been performed for
TMP-SMX.  Both SMX and TMP inhibit key steps
in DNA synthesis.  Either compound alone is
bacteriostatic against most bacteria, but the
combination is highly bactericidal against many
bacterial species.
In our study, the concentration of drug
appeared to play an important role in bacterial
killing.  In time-kill assays at 1 x MIC, TMP-SMX
was bacteriostatic against all three GISA isolates.
At simulated peak serum concentrations, TMP-
SMX was bactericidal against two of the three
strains.  Although activity appears to be strain
specific, the high drug concentration:MIC ratio
may be responsible for the rapid and complete
eradication of organisms in these two strains.  At
simulated peak serum concentrations of 9.8–39.2
x MIC, complete eradication of the organism
occurred in two of three strains, with a greater
than 2-log cfu/ml colony count reduction in the
third strain.  This may represent a concentration-
dependent effect of the drug against this
organism.
Data from the in vitro model seem to confirm
this concentration-dependent antibacterial effect.
For two of the three isolates tested (992 and
14379), greater colony count reduction was
observed with the 15-mg/kg/day dosage than
with the 8-mg/kg/day dosage.  Both dosages were
equally effective against the third isolate (MU50).
Development of resistance appeared to be the
cause of this discrepancy in isolate 992, with a 6-
fold increase in TMP-SMX MIC at 48 hours for
the strain exposed to 8 mg/kg/day.  The MIC did
not change when the isolate was exposed to
TMP-SMX 15 mg/kg/day.  Similarly, postexposure
MICs were unchanged for the other two isolate-
dosage combinations.  The difference in results
between time-kill testing and the model is likely
due to the static nature of the time-kill assay.
The role of TMP-SMX in management of
infections caused by GISA remains unclear.
Advantages of TMP-SMX are its low cost, the
extensive clinical experience with its use, and the
potential to conserve antibiotics with unique
gram-positive activity for situations in which no
alternative therapies exist.  However, no data are
available for TMP-SMX monotherapy in patients
with GISA infection, and only one case report
describes its use in combination for this purpose.
Conclusion
Our results from MIC testing, time-kill assays,
and an in vitro pharmacodynamic model of
infection show that TMP-SMX has activity
against three GISA isolates.  In addition, it
appears that TMP-SMX may have concentration-
dependent antibacterial activity against these
organisms.  This agent has been used successfully
in patients infected with MRSA and GISA.
Further studies should evaluate the activity of
TMP-SMX in combination with other antibiotics
against GISA, as well as in combination with the
human immune system to provide a better
prediction of its clinical efficacy.
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